Oral administration of vanadate to diabetic streptozotocintreated rats decreased the high blood glucose and D-3-hydroxybutyrate levels related to diabetes. The increase in the expression of the P-enolpyruvate carboxykinase (PEPCK) gene, the main regulatory enzyme of gluconeogenesis, was counteracted in the liver and the kidney after vanadate administration to diabetic rats. Vanadate also counteracted the induction in tyrosine aminotransferase gene expression due to diabetes and was able to increase the expression of the glucokinase gene to levels even higher than those found in healthy animals. Similarly, an induction in pyruvate kinase mRNA transcripts was observed in diabetic vanadate-treated rats. These effects were correlated with changes on glucokinase and pyruvate kinase activities. Vanadate treatment caused a decrease in the expression of the liver-specific glucose transporter, GLUT-2. Thus, vanadate was able to restore liver glucose utilization and block glucose production in diabetic rats. The increase in the expression of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCoAS) gene, the key regulatory enzyme in the ketone bodies production pathway, observed in diabetic rats was also blocked by vanadate. Furthermore, a similar pattern in the expression of PEPCK, GLUT-2, HMGCoAS, and the transcription factor CCAAT/ enhancer-binding protein a genes has been observed. All of these results suggest that the regulation of the expression of genes involved in the glucose and ketone bodies metabolism could be a key step in the normalization process induced by vanadate administration to diabetic rats. (J. Clin.
Introduction
The main alterations related to the diabetic process are hyperglycemia and ketoacidosis. The increase in blood glucose is mainly the result ofthe impairment ofeither liver or peripheral tissues to metabolize glucose and the activation ofgluconeogenesis in the liver and the kidney ( 1). Hepatocytes are able to respond to fluctuations in blood glucose levels by parallel changes in the rate of glucose phosphorylation. The key en-zyme in the regulation ofthis process is glucokinase. The regulation of glucokinase activity has been strongly correlated with corresponding changes of mRNA and with rates of transcription of the glucokinase gene (2) (3) (4) (5) (6) . In diabetic animals, where glycolysis is inoperative and gluconeogenesis is increased, glucokinase mRNA is very low (3, (5) (6) (7) (8) (9) (10) . Treatment of diabetic rats with insulin induces glucokinase gene transcription (8) . Another key step in liver glucose metabolism is pyruvate kinase, which plays a central role in the regulation of the glycolytic pathway ( 11) . These controls include short-term regulation, such as inactivation of the L-type enzyme by phosphorylation (12) (13) (14) , and long-term regulation by changes in the amount of the enzyme. The alterations in the amount of this enzyme are primarily due to changes in the level of transcription of its gene ( 15, 16) . Thus, mRNA concentrations, which are decreased in starvation and diabetes, are restored to normal by refeeding the animals a high carbohydrate diet and insulin administration ( 17, 18) .
The cytosolic form of P-enolpyruvate carboxykinase (PEPCK)' is the main regulatory enzyme of gluconeogenesis ( 19) . PEPCK has no known allosteric modifiers and responds to changes in metabolic flux over the gluconeogenic pathway by a rapid increase in enzyme protein ( 19) . PEPCK activity is regulated by different agents through the modification of the synthesis rate ofthe enzyme ( 19) . During the diabetic process, the expression of the liver PEPCK gene is markedly increased by the lack of insulin and the rise of glucagon levels (20) (21) (22) . Insulin administration to streptozotocin-induced diabetic rats results in a decrease of liver PEPCK mRNA levels to those levels found in normal animals. The insulin effect (23) (24) (25) is mainly due to an inhibition of PEPCK gene transcription. On the other hand, insulin has no effect on kidney PEPCK mRNA levels, which are mainly controlled by the body acid-base status. The production of,B-hydroxybutyrate and acetoacetate in diabetic acidosis results in an induction of kidney PEPCK mRNA concentration (26, 27) . Liver ketogenesis supplies metabolic fuels for energy to peripheral tissues. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA 'synthase (HMGCoAS) is the key enzyme in the regulation of ketone bodies synthesis (28) (29) (30) . The gene for HMGCoAS has been cloned (3 1 ); its expression is rapidly changed in response to AMP, insulin, dexamethasone, and refeeding and is greatly increased by starvation and diabetes (32).
Several reports have shown that vanadate acts as an insulinlike effector in vivo by normalizing blood glucose levels in diabetic animals (33) (34) (35) (36) and by preventing the decline in cardiac performance due to this pathological process (33) . Vanadate is also able to modify carbohydrate metabolism in both the intact animal (34, 37) and in isolated cells (38) (39) (40) (41) (42) (43) and tissues (44) . Furthermore, vanadate has been found to be a powerful inhibitor of PEPCK and tyrosine aminotransferase (TAT) gene expression in hepatoma cells (45) . However, vanadate induces the expression of L-pyruvate kinase and glucokinase genes in hepatocytes in primary culture (46) . The 5' flanking region of the PEPCK gene contains regulatory elements that are responsive to cAMP (47) (48) (49) (50) (51) (52) , glucocorticoids (48) (49) (50) , insulin (24, 53) , and vanadate (45) . No insulin or vanadate regulatory elements have been described in glucokinase and pyruvate kinase promoters. It has been suggested that CCAAT/enhancerbinding protein a (C/EBPa), a transcription factor that is highly expressed in liver and adipose tissue, could have a physiological function regulating the transcription of genes coding for enzymes of energy metabolism (54) . The promoters of genes involved in this metabolism have been found to be transactivated by C/EBPa in vitro (52, 54, 55 Treatment ofanimals. Male Sprague-Dawley rats ( 180-230 g) were used. Diabetic animals were obtained by applying a single intravenous injection of streptozotocin (60 mg/kg body wt), dissolved in a 10 mM sodium citrate solution with 0.9% NaCl, pH 4.5, immediately before administration. Diabetic rats were used 7 d after streptozocin treatment. Each diabetic state was assessed by measuring glucosuric and ketonuric levels (Gluketur Test; Ames). The animals were divided into three groups: control, diabetic, and vanadate-treated diabetic. Each group consisted of five rats. The controls and diabetic rats drank a 0.5-g/ 100 ml NaCI solution. The vanadate-treated animals drank a 0.5-g/ 100 ml NaCl solution containing freshly prepared sodium orthovanadate (0.7 mg/ml). 15 d after treatment the animals were killed, blood was collected, and livers and kidneys were removed and quickly frozen in liquid N2. This protocol was repeated three times. Finally, a second series of experiments was performed in which the animals were divided into four groups, each one consisting of five animals: control, vanadate-treated control, diabetic, and vanadate-treated diabetic. This procedure was repeated twice and the protocol followed was as described above.
Enzyme and metabolite assays. Glucose was measured by the hexokinase method (GlucoQuant system; Boehringer Mannheim Biochemicals). D-3-hydroxybutyrate was determined by the D-3-hydroxybutyrate dehydrogenase technique (Boehringer Mannheim Biochemicals).
Serum alanine aminotransferase (SALT) activity was assayed enzymatically (Boehringer Mannheim Biochemicals). Serum insulin concentration was quantified by radioimmunoassay (system INSIK-5; Soren Biomedica, Saluggia (Vercelli), Italy). To determine pyruvate kinase activities, the liver was homogenized in an ice-cold buffer containing 100 mM potassium fluoride, 15 mM EGTA, and 50 mM glycilglycine, pH 7.4. To measure glucokinase activity, liver samples were homogenized in an ice-cold buffer, pH 7.4, containing 50 mM Tris-HCl, 300 mM sucrose, 100 mM KCI, 1 mM EDTA, and 0.7 ul/ml fl-mercaptoethanol. These activities were analyzed in 12,000 g as described in references 56 and 57, respectively. Pyruvate kinase activity was determined at 0.15 mM P-enolpyruvate (active form) and at 5 mM P-enolpyruvate (total activity) (56) . Glucokinase activity was calculated as the difference between the glucose phosphorylation capacity at 100 and 0.5 mM glucose (57) .
Northern analysis. Total RNA was extracted from tissues by the guanidine isothiocyanate method (58) , and the RNA samples (20 Mg) were subjected to electrophoresis on 1% agarose gel containing 2.2 M formaldehyde. Northern blots were hybridized to 32P-labeled cDNAs. The PEPCK cDNA probe corresponded to a 1.1-kb PstI-PstI fragment from the 3' end of the PEPCK cDNA; TAT cDNA corresponded to a 600-b PstI-PstI fragment that included the 3' end of the TAT cDNA; HMGCoAS, a 1,500-bp EcoRI-EcoRI fragment from the cDNA; glukokinase cDNA, a 2.3-kb EcoRI-EcoRI fragment containing the fulllength cDNA; pyruvate kinase cDNA, a 1.6-kb PstI-PstI fragment from the cDNA; GLUT-2 cDNA, a 1.5-kb EcoRI-EcoRI fragment from the cDNA; C/EBPa cDNA, a 1.9-kb BamHI-HindIII fragment from the cDNA. The ,B-actin probe corresponded to a 1.3-kb EcoRI-EcoRI fragment of,B-actin cDNA. These probes were labeled using [a-32P]dCTP, by following the method of random oligopriming as described by the manufacturer. The specific activity of the DNA probe labeled in this manner was -109 cpm/,ug DNA. Hybridization and washing conditions have been described previously (45) . The membranes were exposed to Kodak XAR-5 film, and densitometric analysis of autoradiograms was performed at nonsaturating exposures with a scanning densitometer. The actin signal was used to correct for loading inequalities as an internal standard.
Presentation of the data and statistical analysis. Any variability attributable to the experimental procedures was ruled out because in studies of individual RNA samples the correlation coefficient between increasing amounts of input RNA and signal intensity was 0.99 for all transcripts. To analyze the effects of perturbations independently of variability in basal gene expression, the densitometric readings ofexperimental samples were expressed as a percentage of readings in paired samples of nontreated control rats (always tested in the same Northern blot) after correction for loading differences with the actin signal. The data were summarized with the mean±SEM. Statistical analysis was carried out by analysis ofvariance followed by the Newman-Keuls test for multiple comparisons (59) . Differences were considered statistically significant at P < 0.05.
Results
Effects of vanadate on serum parameters. In agreement with previous reports (33-36), a 15-d treatment of streptozotocin diabetic rats with vanadate decreased the blood glucose levels, which had been augmented in the diabetic state (Table I ). This glucose normalization was a result of vanadate action since no increase in blood insulin was detected in diabetic vanadatetreated animals (Table I ). In addition, vanadate restored body weight and fluid intake of diabetic animals ( more, vanadate induced a strong reduction (-75%) in the increased levels ofD-3-hydroxybutyrate caused by diabetes (Table I). These results agreed with a normalization in the metabolic state in the diabetic animals after treatment. We also measured SALT activity, since it is one ofthe most commonly used parameters to detect hepatic damage. As shown in Table I , streptozotocin treatment induced a significant increase in this enzymatic activity in serum. Vanadate administration to these animals resulted in a decrease of SALT activity to the levels of healthy animals, suggesting that this compound was able to restore the liver tissue to normal status in diabetic rats.
Effects of vanadate on glucokinase and pyruvate kinase gene expression and enzyme activity in normal and diabetic rats. Since vanadate was able to normalize blood glucose levels when administered to diabetic rats, a possible mechanism to explain this action might involve an induction in glucokinase gene expression. Total RNA was isolated from the liver of normal and diabetic animals and analyzed by Northern blotting. Although no significant differences were detected in vanadatetreated control animals (96±15% of nontreated controls), oral treatment ofdiabetic rats with vanadate caused an induction of liver glucokinase mRNA concentrations, which increased from 10±5% in nontreated diabetic rats to 255±72% in vanadatetreated diabetic rats (P < 0.01), related to control nontreated animals ( Fig. 1 A) . A similar pattern was observed when glucokinase activity was determined in the liver of the animals. As shown in Table II , oral treatment with vanadate of control rats did not cause any significant modification ofglucokinase activity compared with control nontreated animals. The glucokinase activity ofdiabetic rats was very low, but a great increase in the enzyme activity was noted in diabetic rats treated with van C CV D DV adate (Table II) . This increase was even higher than that observed in control animals (-60%).
An increase ofglucose utilization through hepatic glycolysis could also contribute in decreasing hyperglycemia. When Ltype pyruvate kinase gene expression was determined, very low concentrations of pyruvate kinase mRNA ( 15±8% of the nontreated control) were detected in diabetic livers. However, a 160±30% induction in the three pyruvate kinase mRNA transcripts of 3.2-, 2.2-, and 2.0-kb was observed after vanadate treatment of diabetic rats (Fig. 1 B) . No significant changes were observed in the concentration of pyruvate kinase mRNA in control animals treated with vanadate compared with control nontreated rats ( 106±19%). The changes in pyruvate kinase activity showed a pattern similar to that detected in mRNA concentrations. Both pyruvate kinase activities at low (active form) and high (total activity) concentrations of the substrate were not modified by vanadate treatment of control animals, whereas the effector was able to counteract the inhibition of the enzyme caused by diabetes (Table II) .
Effects ofvanadate on PEPCK and TA Tgene expression in normal and diabetic rats. To decrease blood glucose levels, in addition to stimulating glucose use, vanadate may decrease glucose production through gluconeogenesis. In this regard, we studied the effects of vanadate treatment on the expression of the PEPCK gene in the liver and kidney ofhealthy and diabetic animals, since the activity of PEPCK is regulated at the level of the transcription of its gene. Fig. 2 shows that diabetes caused an increase of 660±118%, related to control rats, in the expression of the liver PEPCK gene. The administration of vanadate produced a significant reduction of these mRNA concentrations up to 240±80% of the control animals. However, no significant modification was observed on PEPCK mRNA concentrations in the liver of control rats treated with vanadate (data not shown). In addition, we also detected a 550±100% increase in the kidney PEPCK mRNA concentrations in diabetic rats compared with control animals and a reduction to 220±35% after treatment with vanadate (Fig. 3) . These results show that the administration of vanadate to diabetic animals was able to affect the expression ofthe PEPCK gene in different tissues. We also investigated the effects of vanadate on TAT, another enzyme related to gluconeogenesis and regulated at the level of gene expression in a similar manner as PEPCK (60-62). cAMP and glucocorticoids induce the expression of the gene whereas insulin inhibits TAT gene expression (63, 64) . In this study a similar pattern of modification (480±70% induction caused by diabetes and reduction to 180±38% after vanadate treatment) of the expression of the gene for TAT was detected (Fig. 4) .
Effects of vanadate on liver glucose-transporter GLUT-2 gene expression. GLUT-2, the liver-and pancreas-specific glucose transporter, is involved in glucose uptake and release processes (65 ) . Insulin treatment ofdiabetic animals decreases the amount of protein and mRNA of GLUT-2 (66) . However, little is known about the regulation of the expression of this glucose transporter in the liver. We analyzed the effects of diabetes and vanadate administration on the expression of this glucose transporter. a 220±45% induction in GLUT-2 gene expression, vanadate treatment of diabetic rats reduced the mRNA concentrations to those detected in the liver ofhealthy animals (85±18%). No changes of the GLUT-2 mRNA concentrations were noted in control animals treated with vanadate compared with control nontreated animals (data not shown).
Effects ofvanadate on mitochondrial HMGCoAS gene expression. As already described in Table I , vanadate treatment provoked a 75% reduction in the increased levels of D-3-hydroxybutyrate caused by diabetes. Thus, we next investigated the effect of vanadate treatment on the expression of the mitochondrial HMGCoAS gene. Fig. 6 shows that although diabetes produced an increase (270±52% over the control nontreated rats) in specific HMGCoAS mRNA concentrations, vanadate administration to diabetic rats caused a decrease of these concentrations (to 120±28% of nontreated control animals), which resulted in a normalization of the expression of the gene in these animals. Effects ofvanadate administration to the C/EBPa gene expression. To investigate a role of C/EBPa in the regulation of the expression of the genes involved in key steps in the regulation ofcarbohydrate and ketone bodies metabolism, we further analyzed the expression of this gene in the liver of diabetic and diabetic vanadate-treated rats. Fig. 7 shows that although vanadate treatment did not produce any significant effect on C/ EBPa mRNA concentrations in control rats, diabetes caused an induction in the expression of liver C/EBPa (142±28% of nontreated control animals). However, when the animals were treated with vanadate, a decrease of C/EBPa mRNA concentrations was detected compared with diabetic rats. The concentration of C/EBPa mRNA reached in diabetic treated animals was lower than in control nontreated animals (70±14%).
Discussion
In this study, we have investigated the role ofvanadate in restoring the normal metabolic state in diabetic animals. In the last few years, many reports have been available regarding the insulin-like actions of vanadate in regulating glucose metabolism either in vivo (33) (34) (35) (36) (37) In our study, the expression of the gene for TAT, an enzyme also related with gluconeogenesis, was regulated like PEPCK. TAT gene expression is restricted to parenchymal cells of the liver (71) and it is activated by glucocorticoids and glucagon (60-62). TAT expression is undetectable during gestation but increases rapidly within the first hours after birth as a result of the increase in the glucagon/insulin ratio in newborn animals (72) . The increase in this ratio could be the cause of the high expression of the TAT genes in diabetes. Vanadate treatment was able to block the induction of TAT mRNA levels, suggesting that vanadate may interfere with the cAMP-mediated activation of the TAT promoter. However, no data are available regarding the effects of vanadate on specific transcription factors involved in the control of this promoter.
Like insulin, vanadate not only decreases gene expression, it is also able to induce the expression of the genes for glucokinase and pyruvate kinase in primary cultured hepatocytes (46) . The results presented in this paper indicate that vanadate treatment also induces the expression of these genes in the intact animal, which is impaired by the diabetic process. However, no changes in the expression of both genes are detected in healthy rats treated with vanadate. Furthermore, vanadate treatment of diabetic rats also causes an induction in glucokinase and pyruvate kinase mRNA concentrations. This effect is also found in cultured hepatocytes, where the induction of these genes is higher in the presence of glucose (46) . Blood glucose levels detected in vanadate-treated diabetic animals are 1 .5-fold higher than in controls, which might be responsible for the increase in the expression of both genes. Despite several reports describing glucokinase and pyruvate kinase gene promotor regulatory regions, the mechanism by which vanadate regulates the expression of both genes is still not known and responsive elements to this effector have not yet been described. The effects of vanadate on glucokinase and pyruvate kinase mRNA concentrations are directly related with glucokinase and pyruvate kinase activities. These results are in agreement with previous reports that indicate that vanadate administration to diabetic rats restores 6-phosphofructo-2-kinase and glucokinase activities (34) . Regarding glucose transport, the liver plays a dual role in that glucose uptake occurs from circulation when gluconeogenesis and glycogenolysis are low, but it releases glucose when gluconeogenesis and glycogenolysis are activated, such as in the insulin-deficient diabetic state. Diabetic rats presented an increase in the amount of protein and mRNA for . Insulin treatment of these animals decreased the amount of protein and mRNA toward levels observed in nondiabetic animals (66) . A great efflux of glucose occurs from the liver in the absence of insulin and the glucose transporter plays an important role in this condition. However, it has recently been suggested that the increase in GLUT-2 mRNA levels observed in a diabetic liver could be attributed to high glucose concentrations rather than to insulin deficiency (73) .
It has been suggested that regulation of energy balance could be channeled through the liver-enriched transcription factor C/EBPa. The concentration of C/EBPa increased dramatically in the liver of the fetal rat 3 d before birth (74) . The expression of PEPCK (75) t E p hours after birth. Moreover, Cios albino-mutant mice, which lack the "hepatocyte-specific developmental regulation" (hsdr-1) locus on chromosome 7, showed a strong reduction oftranscription rates of the C/EBPa gene shortly before birth and failed to activate a group of hepatic enzymes perinatally (54, 76) . One subset of such affected genes includes PEPCK, serin dehydratase, glucose 6-phosphatase, TAT, and aldolase B, which are involved in gluconeogenesis. These mice died a few hours after birth, presumably as a consequence of hypoglycemia. C/EBPa has been shown to transactivate PEPCK in vitro (54, 76) and our results indicated that this transcription factor was induced by diabetes, suggesting that C/EBPa could affect PEPCK gene expression in vivo. Similarities were found between C/EBPa and PEPCK, HMGCoAS, and GLUT-2 genes regarding their pattern of expression. Vanadate may act on these subsets ofgenes involved in energy metabolism at least in part through the regulation of C/EBPa. The observations that C/EBPa avidly binds to cAMP response element-1 (CRE-1) on the PEPCK promoter, which overlaps the sequence described to be responsive to vanadate (42), and that there is an inhibition of both C/EBPa and PEPCK gene expression in diabetic rats after vanadate administration, suggested that vanadate may act on the expression of the PEPCK gene through modifications of the C/EBPa transcription factor in vivo.
In conclusion, the increase of the glucokinase and L-pyruvate kinase mRNA concentrations and the inhibition of PEPCK gene expression may contribute to the decrease of blood glucose levels observed after oral treatment with vanadate. As summarized in Fig. 8 , the induction of glucokinase will augment glucose entry into metabolic pathways. The rise ofL-pyruvate kinase will allow the use ofthe newly synthetized glucose 6-phosphate through glycolysis. The inhibition of PEPCK will block liver glucose production, dramatically increased during diabetes, which correlates with the decrease in GLUT-2 expression. On the other hand, the inhibition of HMGCoAS gene expression will result in a decrease on ketone bodies production, which is reflected in the reduction of blood D-3-hydroxybutyrate levels. Finally, vanadate might restore the carbohydrate and ketone bodies metabolism at least in part through the regulation of specific transcription factors, including members of the C/EBP family involved in the control of energy metabolism.
